Company Profile

Company Profile

Name
Myoridge Co. Ltd.
President
Naohiro Makita
Establishment
August 10th, 2016
Email
info@myoridge.co.jp
Tel
075-585-4560
Address
14 Yoshidakawara-cho, Sakyo-ku, Kyoto, 606-8305, Japan
会社の写真

management

  • CEO

    Naohiro Makita

  • CTO

    Issei Minami

  • CMO

    Takeo Suzuki

  • CEONaohiro Makita

    2016
    Graduated from Kyoto University Faculty of Engineering.
    2016
    Established Myoridge Co. Ltd. while in Graduate School of Kyoto University. President (current).

  • CTOIssei Minami

    2003
    Graduated from the doctoral course of Kyoto University Graduate School of Science.
    2003
    Research Assistant, HMRO sleep research group, Kyoto University Graduate School of Medicine.
    2007
    Researcher, Incorporated Non-profit Organization Stem Cell Drug Discovery Institute.
    2010
    Researcher and later assumed Assistant Professor position, Kyoto University, Institute for Integrated Cell-Material Sciences (iCeMS).
    2016
    Established Myoridge Co. Ltd. while in Kyoto University iCeMS. Engineering Adviser and later assumed Board Director and CTO positions (current)
    2017
    Specially Appointed Associate Professor, the joint research chair of Cell Design for Tissue Construction, Graduate School of Medicine, Osaka University.
    2021
    Visiting Associate Professor, Podiatry Division, Plastic Surgery Department, Surgery Course, Kobe University Graduate School of Medicine (current)

  • CMOTakeo Suzuki

    2008
    Graduated from the master course of Chiba University Graduate School of Medical and Pharmaceutical Sciences.
    2008
    Clinical Development Division, Eli Lilly Japan K.K.
    2012
    Clinical Development Department, Japan Tissue Engineering Co., Ltd., later established CDMO Business Department. Concurrently worked in Regenerative Medicine Business Development Department, Fujifilm Corporation.
    2020
    CMO, Myoridge Co. Ltd. and later assumed Board Director of Operations and CMO positions (current)
Masaaki Fujiwara
Chief Strategy Officer （CSO）
Makoto Taketani
Outside Director
Mitsuhiko Inaba
Full-time Auditor
Nobuhiro Kidachi
Management Finance Adviser

Related papers

  • Takaaki Samura, et al.,　 Laminin-221 Enhances Therapeutic Effects of Human-Induced Pluripotent Stem Cell–Derived 3-Dimensional Engineered Cardiac Tissue Transplantation in a Rat Ischemic Cardiomyopathy Model. Journal of the American Heart Association. 2020 Nov 14.
  • Kazuki Harada, et al.,　 Green fuorescent protein based lactate and pyruvate indicators suitable for biochemical assays and live cell imaging. Scientific Reports. 2020 Nov 11.
  • Yuji Shiba, Toshihito Gomibuchi, Tatsuichiro Seto, Yuko Wada, Hajime Ichimura, Yuki Tanaka, Tatsuki Ogasawara, Kenji Okada, Naoko Shiba, Kengo Sakamoto, Daisuke Ido, Takashi Shiina, Masamichi Ohkura, Junichi Nakai, Narumi Uno, Yasuhiro Kazuki, Mitsuo Oshimura, Itsunari Minami, Uichi Ikeda, MHC-matched allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates non-human primate hearts. Nature. 2016 Oct 28.
  • Kadota S, Minami I, et al.,　Development of a reentrant arrhythmia model in human pluripotent stem cell-derived cardiac cell sheets. European Heart Journal. 2013 April 34.
  • Minami I, et al.,　A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine- and xeno-free conditions. Cell Reports, 2012 Nov 29.

上に戻る